early deaths as the most significant threat to apl
play

Early deaths as the most significant threat to APL pa7ents in real - PowerPoint PPT Presentation

Feb 03, 2024 •271 likes •605 views

Early deaths as the most significant threat to APL pa7ents in real life Soren Lehmann, MD, PhD Department of Medical Sciences Uppsala University and Uppsala University Hospital and Karolinska Ins7tute, Stockholm Sweden History of ED data

  1. Early deaths as the most significant threat to APL pa7ents in real life Soren Lehmann, MD, PhD Department of Medical Sciences Uppsala University and Uppsala University Hospital and Karolinska Ins7tute, Stockholm Sweden

  2. History of ED data from the Swedish Registry In late 2000 th , we first evaluate APL data from the Swedish Acute • Leukemia registry 1997-2006 Surprising data with an ED rate of approximately 30% in this popula7on- • based APL cohort – contrast to clinical trials Reported first 7me here in Rome 2009 • One previous Brazilian study during the ATRA era reported an similar ED • rate (Jacomo et al. 2007) This has been followed by several other popula7on-based or hospital • based reports with ED rates between 10 and 30%.

  3. ED in popula7on-based studies Study& n& Study&years& Age& High&risk& ED&30& Death&by& (median)& patients& (%)& bleeding& (%)& (%)& Jacomo&2007& 132& 2003,2006& 36**& 36.9& 13&(5d)& 67& 26&(14d)& 32&(ind***)& Lehmann&2011& 105& 1997,2006& 54& 34& 22&(d7)& 41& 29&(d30)& Park&2011& 1400& 1992,2007& 44& & 17.3&(1&mo)& & McClellan&2012& 70& 1997,2009& 50& 35& 19&(7d)& 54& 26&(30d)&& Altman&2013& 204& 1992,2009& 47.5& 25& 4.9&(7d)& 61& 11&(30d)& Rahme&2014& 399& 2006,2011& 51& 27& 9.6&(30d)& 31& Paulsen&2014& 399& 1993,2007& & & 21.8& & (register,based)& 131& 1999,2009& 47.9*& 20.6& 14.6& & (hospital,based)& Abrahao&2015& 722& 1988,2011& 0,39*& & 11(7d)& & 17&(30d)& Lehmann&2017& 195& 1997,2013& 56& 30& 25&(30d)& 46& &

  4. ED in clinical trials in the ATRA era ! ! n! Study!years! Induction! Age! High!risk! ED30! Death!by! treatment! (median)! patients! (%)! bleeding! (%)! (%)! Di!Bona!2000! 123! 1989E1993! IDA!only! 38! ! 7.3!(D10)! 35! ! 16,2! (D40)! Di!Bona!2000! 499!! 1993E1997! AIDA! 39! ! 3.8!(D10)! 50! ! 7.6!(D40)! Fenaux!1993! 101! 1991E1992! ATRA!alone!or! 40! 28! 9!v!8! 67! CHEMO! Tallman!1997! 346! 1992E1996! ATRA!alone!or! 38! 21! 11!vs.!14! 53! CHEMO! %!(28d)! Asou!1998! 196! 1992E1994! ATRA*!! 46! 26! 9! 94! Avvisati!1996! 20! 1993! AIDA! 35! 25! 10! 50! Lo!Coco!2010! 642! 1993E2000! AIDA! 38! 27.6! 5.5! 37! Lo!Coco!2010! 453! 2000E2006! AIDA! 41! 28.5! 5.6! 32! Fenaux!1999! 413! 1993E1996! ATRA!alone!or! 46! 39! 7! 32! ATRA!+!CHEMO! (WBC>5)! Lengfelder!2000! 51! 1994E1999! ATRA!+!CHEMO! 43! 22! 8! 75! Schelnk!2004! 82! 1995E2003! AIDA! 43! 22! 12! 71! Sanz!1999! 123! 1996E1998! AIDA! 42! ! 9.8! 67! De!la!Serna!2008! 732! 1996E2005! AIDA! 40! 25! 9.0! 56! Powell!2010! 481! 1999E2005! ATRA!+!CHEMO! ! 23! 8! ! Yanada!2007! 279! ! ATRA**!! ! ! 3! 89! ! Lengfelder!2009! 142! 1994E2005! ATRA!+!CHEMO! 40! 26! 7.7! 67! Ghavamzadeh! 197! 1999E2010! ATO! 29! 19! 14.7! 90! 2011! Illand!2012! 124! 2004E2009! ATRA!!+!ida!+! 44! 20! 3.2! 50! ATO! Shen!2004! 61! 2001E2003! ATO!vs.!ATRA! 30,!40,! 23! 6.6! 100! vs.!ATRA!+!ATO! 34! Ravandi!2008! 82! 2002E2008! ATRA!+!ATO!+! 47! 32! 8.5! ! GO!for!high!risk! Lo!Coco!2013! 162! 2007E2010! ATRA!+!ATO!vs.! 44.6!vs! 0! 5.2!vs.!0! 0! AIDA! 46.6! Burnett!2015! 235! 2009E2013! ATRA!+!ATO!vs.! 47! 24! 4!vs.!6! 0!with!ATO! AIDA! 5!vs.!9! 27!in!AIDA! (60D)!

  5. Pre-ATRA studies ! Study& n& Study& Treatment& Age& High&risk& ED& Death&by& years& (median)& patients& (%)& bleeding& (%)& (%)& Bernard!1973! 80! 1963/1971! DNR!(after!1969),! ! ! 25!(5d)! ! 6/MP,!prednisone,! 50!(3!w)! metotraxate!metyl! GAG! Drapkin!1977! 24! 1970/1976! Ara/C,!6/TG,!DNR! 39! 33! 54! 85! Cordonnier!! 57! 1972/1982! Ara/C!and!DNR! 41*! 23!(>15)! 12!(5d)! 84!(5d)! 1985! 47*! 41*! Kantrajian!1986! 60! 1973/1984! Ara/C,!Amsa,! 34! 30! 26***! 65!of!all!EDs! vincristine,! 43! prednison,! antracyclins! Hoyle!1987! 115! 1976/1986! DNR,!Ara/C,!6/TG! <39! ! 33! 84! Sanz!1988! 34! 1976/1986! DNR! 34.5! 24! 29! 60! Rodeghiero! 268! 1984/1987! DNR,!doxorubicin,! 41! 31! 13!(10d)! 74! 1990! Ara/C!and!VP/16! Cunningham! 57! 1974/1984! Amsa,!Ara/C,!6/TG! <39**! 32! 21! 67! 1990! Thomas!1991! 67! 1974/1989! DNM,!Ara/C,! 40! 28! 30! 63! vincristine,!6/TG! Fenaux!1991! 70! 1975/1988! DNR!alone!or! 44! 21! 18! 15! DNR+Ara/C!

  6. Popula7on-based registries • To provide valid data, the registry must have a good coverage (eg. 95%) of the defined popula7on, report relevant parameters with good quality, and have a close to complete follow-up • These studies can give useful results for pa7ent popula7ons that are not covered by clinical studies • A complement to clinical studies to guide management of the pa7ents

  7. Swedish Acute Leukemia Registry Since 1958, a Swedish Cancer Registry, dual report system were all cancers • have to be reported by law by pathologists and the trea7ng clinic. Results in very high coverage. Since 1997, a Swedish registry with detailed informa7on on AML pa7ents. • Con7nuously matched with the Swedish Cancer Registry (98% coverage).

  8. Swedish Acute Leukemia Registry Since 1958, a Swedish Cancer Registry, dual report system were all cancers • have to be reported by law by pathologists and the trea7ng clinic. Results in very high coverage. Since 1997, a Swedish registry with detailed informa7on on AML pa7ents. • Con7nuously matched with the Swedish Cancer Registry (98% coverage). Lehmann et al Leukemia 2011

  9. Swedish Acute Leukemia Registry Since 1958, a Swedish Cancer Registry, dual report system were all cancers • have to be reported by law by pathologists and the trea7ng clinic. Results in very high coverage. Since 1997, a Swedish registry with detailed informa7on on AML pa7ents. • Con7nuously matched with the Swedish Cancer Registry (98% coverage). Lehmann et al Leukemia 2011

  10. Follow-up a_er 2006 • Informa7on to the Swedish hematology community regarding the risk of ED was intensified from 2009 • Guidelines for the early handling of APL pa7ents s7ll the same as before but more forcefully communicated – Start ATRA on all AML pa7ents with slightest suspicion of APL (without molecular analysis) – Transfusion of platelets to keep platelets > 30-50 x 10 9 /L – Plasma or fibrinogen concentrates as long as signs of coagulopathy and in order to keep fibrinogen > 1.5 g/L • We used from 2009 as a study period represen7ng increased awareness

  11. Follow-up a_er 2006 • Informa7on to the Swedish hematology community regarding the risk of ED was intensified from 2009 • Guidelines for the early handling of APL pa7ents s7ll the same as before but more forcefully communicated – Start ATRA on all AML pa7ents with slightest suspicion of APL (without molecular analysis) – Transfusion of platelets to keep platelets > 30-50 x 10 9 /L – Plasma or fibrinogen concentrates as long as signs of coagulopathy and in order to keep fibrinogen > 1.5 g/L 80 • We used from 2009 as a 1997 -2008 70 study period represen7ng 60 2009-2013 increased awareness 50 40 2010-2013 30 20 10 0 Day 0 and Day 1 Day 2 or before later

  12. Follow up on ED study a_er 2009 1997-2008 2009-2013 1997-2013 Number of patients 130 65 195 Median age (yrs.) 54 60 56 Mean age (yrs.) 52.4 56.1 53.7 Female (%) 59 46 55 Age >65 (%) 26 37 30 Age >75 (%) 16 10 14 High risk (%) 29 31 30 PS 0-1 71 70 71 2-4 29 30 29 Early death, all (%) 24 26 25 - high risk* (%) 38 50 44 - low and intermediate risk* (%) 19 15 18 ! Lehmann et al Leukemia 2017

  13. Follow up on ED study a_er 2009 1997-2008 2009-2013 1997-2013 Number of patients 130 65 195 Median age (yrs.) 54 60 56 Mean age (yrs.) 52.4 56.1 53.7 Female (%) 59 46 55 Age >65 (%) 26 37 30 Age >75 (%) 16 10 14 High risk (%) 29 31 30 PS 0-1 71 70 71 2-4 29 30 29 Early death, all (%) 24 26 25 - high risk* (%) 38 50 44 - low and intermediate risk* (%) 19 15 18 ! Lehmann et al Leukemia 2017

  14. Follow up on ED study a_er 2009 1997-2008 2009-2013 1997-2013 Number of patients 130 65 195 Median age (yrs.) 54 60 56 Mean age (yrs.) 52.4 56.1 53.7 Female (%) 59 46 55 Age >65 (%) 26 37 30 Age >75 (%) 16 10 14 High risk (%) 29 31 30 PS 0-1 71 70 71 2-4 29 30 29 Early death, all (%) 24 26 25 - high risk* (%) 38 50 44 - low and intermediate risk* (%) 19 15 18 ! Lehmann et al Leukemia 2017

  15. Follow up on ED study a_er 2009 1997-2008 2009-2013 1997-2013 Number of patients 130 65 195 Median age (yrs.) 54 60 56 Mean age (yrs.) 52.4 56.1 53.7 Female (%) 59 46 55 Age >65 (%) 26 37 30 Age >75 (%) 16 10 14 High risk (%) 29 31 30 PS 0-1 71 70 71 2-4 29 30 29 Early death, all (%) 24 26 25 - high risk* (%) 38 50 44 - low and intermediate risk* (%) 19 15 18 ! Lehmann et al Leukemia 2017

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

The Threat from County Lines and Serious Violence Lynne Owens CBE QPM Director General National

The Threat from County Lines and Serious Violence Lynne Owens CBE QPM Director General National

The Threat from County Lines and Serious Violence Lynne Owens CBE QPM Director General National Crime Agency Serious and organised crime leads to more UK deaths per year than all other national security threats combined. 2,600 deaths

293 views • 8 slides
Standard Resuscitation Paradigm Crystalloid 3:1 Ratio Transient or no response Class I

Standard Resuscitation Paradigm Crystalloid 3:1 Ratio Transient or no response Class I

5/30/2013 Transfusion Ratios: Whats the Civilian Trauma Mortality Evidence? 100% 90% 80% Percentage of deaths 70% Hemorrhage COD 60% in 30-40% of 50% 40% early deaths 30% 20% 10% Rachael Callcut, MD, MSPH 0% Prehospital First

488 views • 12 slides
Assessment What is Threat Assessment Threat assessment is the process of gathering

Assessment What is Threat Assessment Threat assessment is the process of gathering

Threat Assessment What is Threat Assessment Threat assessment is the process of gathering information to understand the threat of violence posed by a person. Threat management is the process of developing and executing plans to mitigate

332 views • 15 slides
Responding to an Intensifying Threat Paul Walton CBD Hierarchical Approach Prevention Early

Responding to an Intensifying Threat Paul Walton CBD Hierarchical Approach Prevention Early

INNS, Borders and Biosecurity Responding to an Intensifying Threat Paul Walton CBD Hierarchical Approach Prevention Early detection and Rapid response Control Efforts to mitigate invasions have not been effective enough to keep up

390 views • 20 slides
Phases of Disaster Despair Threat Threat Phase: Small events serve as a warning or threat to

Phases of Disaster Despair Threat Threat Phase: Small events serve as a warning or threat to

Honeymoon Threat Restoration Rescue Phases of Disaster Despair Threat Threat Phase: Small events serve as a warning or threat to normal living. A disaster has not yet oc- curred, but there is a sense of impending doom. Individual

604 views • 6 slides
What Does This Advanced Threat Landscape Look Like? Advanced Threat Landscape

What Does This Advanced Threat Landscape Look Like? Advanced Threat Landscape

DDoS &amp; Modern Threat Motives Dan Holden Director, ASERT What Does This Advanced Threat Landscape Look Like? Advanced Threat Landscape Geo-poli:cal More defenses ? App/Content t a

1.13k views • 44 slides
Total Annual Gun Deaths Total Annual Gun Deaths 34,000 150 1st world countries with fewer

Total Annual Gun Deaths Total Annual Gun Deaths 34,000 150 1st world countries with fewer

USA: UK: Total Annual Gun Deaths Total Annual Gun Deaths 34,000 150 1st world countries with fewer guns suffer fewer gun deaths There have been more than 1600 mass shootings in America since Sandy Hook States with tighter gun control

226 views • 12 slides
Active Threat on Campus Prevention &amp; Response Active threat defined An active threat can be

Active Threat on Campus Prevention &amp; Response Active threat defined An active threat can be

Active Threat on Campus Prevention &amp; Response Active threat defined An active threat can be defined as: A person whose immediate activity can cause death and/or serious injury An active threat can involve a firearm or another

395 views • 15 slides
IMMray platform Proprietary blood-based biomarker platform Significant unmet medical need for

IMMray platform Proprietary blood-based biomarker platform Significant unmet medical need for

IMMray platform Proprietary blood-based biomarker platform Significant unmet medical need for early Initial addressable market in EU/US: USD 4.4bn Familial, new onset diabetes type II, early symptoms detection of pancreatic cancer Near-term

443 views • 40 slides
Offensive Threat Modeling for Attackers turning threat modeling on its head Rafal M. Los

Offensive Threat Modeling for Attackers turning threat modeling on its head Rafal M. Los

Offensive Threat Modeling for Attackers turning threat modeling on its head Rafal M. Los Chief Security Evangelist HP Software Shane MacDougall Principal Tactical Intelligence Modern threat modeling is a defensive response to

783 views • 52 slides
Main Points Sunday Early Monday Severe Threat Increasing severe weather risk from Sunday

Main Points Sunday Early Monday Severe Threat Increasing severe weather risk from Sunday

Main Points Sunday Early Monday Severe Threat Increasing severe weather risk from Sunday afternoon through pre-dawn hours Monday Highest severe risk is along and south of I-20 Two possible rounds of severe thunderstorms

367 views • 10 slides
Initial Progress Road traffic deaths: the facts 3 Million people 1.3 million deaths 2 1.8 20

Initial Progress Road traffic deaths: the facts 3 Million people 1.3 million deaths 2 1.8 20

Initial Progress Road traffic deaths: the facts 3 Million people 1.3 million deaths 2 1.8 20 50 million injured 1.3 1.3 1 &lt;1 AIDS related deaths Tuberculosis Road traffic Malaria UNAIDS 2008 WHO 2007 WHO 2004 WHO 2008 Goal of the

514 views • 29 slides
Threat Modeling and S haring S ummary Proposal to kick off Threat Modeling proj ect

Threat Modeling and S haring S ummary Proposal to kick off Threat Modeling proj ect

Threat Modeling and S haring S ummary Proposal to kick off Threat Modeling proj ect Multi-phase approach Initially: create Cyber Domain PIM and S TIX PS M with UML Profile for NIEM Expand to other PS M, create Threat Meta

211 views • 10 slides
Proposed Low-Threat Petroleum UST Closure Policy SWRCB Low-Threat UST Closure Policy Task Force

Proposed Low-Threat Petroleum UST Closure Policy SWRCB Low-Threat UST Closure Policy Task Force

Proposed Low-Threat Petroleum UST Closure Policy SWRCB Low-Threat UST Closure Policy Task Force Los Angeles RWQCB Presentation September 15, 2011 Prologue Low-Threat Policy: An Evolutionary Process STATE WATER RESOURCES CONTROL BOARD

528 views • 31 slides
THE NATIONAL ECONOMY DISRUPTIVE EPIDEMICS AND THE U.S. ECONOMY U.S. Annual GDP Growth and

THE NATIONAL ECONOMY DISRUPTIVE EPIDEMICS AND THE U.S. ECONOMY U.S. Annual GDP Growth and

THE NATIONAL ECONOMY DISRUPTIVE EPIDEMICS AND THE U.S. ECONOMY U.S. Annual GDP Growth and Epidemic Deaths 1910 - 2020 20% Polio (1916) 7,000 deaths Polio (1946-52) London Flu (1972-73) 7,710 deaths 1,072 deaths 15% Swine Flu SARS

955 views • 56 slides
Early Help Clare Mittelstadt Early Help Manager What is Early Help? Early Help is about

Early Help Clare Mittelstadt Early Help Manager What is Early Help? Early Help is about

Early Help Clare Mittelstadt Early Help Manager What is Early Help? Early Help is about identifying families at the right time and engaging them in the most suitable support to overcome issues and build their own resources and capacity to

232 views • 9 slides
Overview Stroke Case Presentation Current Topics in Stroke Acute Stroke Management

Overview Stroke Case Presentation Current Topics in Stroke Acute Stroke Management

3/22/2017 Overview Stroke Case Presentation Current Topics in Stroke Acute Stroke Management at-a-glance Management Secondary Prevention New Guidelines for Women Kenneth A. Fox, M.D. Assistant Clinical Professor - UCSF

471 views • 12 slides
Dimensional Conceptualization and Diagnosis of NPD APA Atlanta 2016 Elsa Ronningstam, Ph.D .

Dimensional Conceptualization and Diagnosis of NPD APA Atlanta 2016 Elsa Ronningstam, Ph.D .

Dimensional Conceptualization and Diagnosis of NPD APA Atlanta 2016 Elsa Ronningstam, Ph.D . No Conflicts of Interest Objectives 1) outline the DSM-5 Section III hybrid dimensional and trait focused diagnosis for narcissistic

547 views • 36 slides
Targeting PCSK9 in Clinical Practice Guidance and Future JOHN J.P. KASTELEIN PROFESSOR OF

Targeting PCSK9 in Clinical Practice Guidance and Future JOHN J.P. KASTELEIN PROFESSOR OF

Targeting PCSK9 in Clinical Practice Guidance and Future JOHN J.P. KASTELEIN PROFESSOR OF MEDICINE UNIVERSITY OF AMSTERDAM THE NETHERLANDS Faculty Disclosure Declaration of financial interests For the last 3 years and the subsequent 12

404 views • 24 slides
Real-Time Applications Tolerant: can tolerate occasional loss of data. Intolerant: cannot tolerate

Real-Time Applications Tolerant: can tolerate occasional loss of data. Intolerant: cannot tolerate

Real-Time Applications Tolerant: can tolerate occasional loss of data. Intolerant: cannot tolerate such losses. Delay-adaptive: applications that can adjust their playback point (delay or advance over time). Rate-adaptive: can alter the bit rate

218 views • 21 slides
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization the TRILOGY ACS trial On behalf of the TRILOGY ACS Investigators www.clinicaltrials.gov Identifier: NCT00699998 Committees and Disclosures

345 views • 12 slides
Mapping the human brain epigenome and its links to disease Peter Hickey Department of

Mapping the human brain epigenome and its links to disease Peter Hickey Department of

Mapping the human brain epigenome and its links to disease Peter Hickey Department of Biostatistics Johns Hopkins Bloomberg School of Public Health @PeteHaitch Current map of human brain methylome is limited Bulk tissue Limited

258 views • 25 slides
Wat betekent de komst van NOAC antidota voor de klinische praktijk? Professor Saskia Middeldorp

Wat betekent de komst van NOAC antidota voor de klinische praktijk? Professor Saskia Middeldorp

Wat betekent de komst van NOAC antidota voor de klinische praktijk? Professor Saskia Middeldorp | Department of Vascular Medicine | MiddeldorpS Nationale antistollingsdag 6 november 2018 Disclosures Research Support, Advisory Boards

563 views • 28 slides
Integrating the Healthcare Enterprise International IHE Eye Care Webinar Series July 2018

Integrating the Healthcare Enterprise International IHE Eye Care Webinar Series July 2018

Integrating the Healthcare Enterprise International IHE Eye Care Webinar Series July 2018 Peter Scherer, Principal at PS IT International IHE Eye Care Co-Chair Technical Committee Abdiel Marin, CEO EyeMD EMR Healthcare Systems,

412 views • 40 slides

More recommend